Assessing Nuvalent (NUVL) Valuation After Widening Losses And A New US$458.4m Shelf Registration [Yahoo! Finance]
Nuvalent, Inc. - Class A (NUVL)
NASDAQ:AMEX Investor Relations:
nuvelinc.com/company/investor_relations.html
Company Research
Source: Yahoo! Finance
Nuvalent (NUVL) is back in focus after reporting fourth quarter and full year 2025 results that showed a wider net loss, along with a new shelf registration of up to US$458.4 million in Class A shares. See our latest analysis for Nuvalent. The earnings release and fresh shelf registration come after a mixed stretch for the stock, with a 1-year total shareholder return of 45.57% and a 3-year total shareholder return of about 3.4x, while shorter term share price momentum has softened slightly around the current US$102.26 level. If this update has you looking beyond a single cancer drug developer, it could be a good moment to scan our list of 32 healthcare AI stocks and see what else stands out. With shares around US$102.26, widening losses and a sizeable new shelf registration already on the table, the key question is whether Nuvalent is still undervalued or if the market is already pricing in future growth. Price to Book of 6.4x: Is It Justified? Nuvalent currently trades
Show less
Read more
Impact Snapshot
Event Time:
NUVL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NUVL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NUVL alerts
High impacting Nuvalent, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
NUVL
News
- Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026 [Yahoo! Finance]Yahoo! Finance
- Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026PR Newswire
- This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally [Yahoo! Finance]Yahoo! Finance
- Nuvalent (NUVL) had its price target raised by Cantor Fitzgerald from $135.00 to $140.00. They now have an "overweight" rating on the stock.MarketBeat
- Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
NUVL
Earnings
- 2/26/26 - Miss
NUVL
Analyst Actions
- 2/27/26 - Cantor Fitzgerald
NUVL
Sec Filings
- 3/24/26 - Form 144
- 3/20/26 - Form 3
- 3/16/26 - Form 4
- NUVL's page on the SEC website